Australia's Inflation Eases in February but Core Pressures Persist 
ICE Arrests Colombian Journalist in Tennessee, Trump Administration Says She Will Receive Due Process 
ECB Eyes Rate Hike Amid Iran Conflict-Driven Energy Price Surge 
Asian Markets Rally as Oil Prices Tumble and Middle East Peace Hopes Emerge 
Trump Administration Settles Lawsuit Barring Federal Agencies from Pressuring Social Media Censorship 
U.S. Appeals Court Strikes Down FTC Order Against TurboTax "Free" Advertising 
Costco Faces Class Action Lawsuit Over Tariff Refunds as Supreme Court Strikes Down Trump's IEEPA Tariffs 
FEMA Reinstates $1 Billion Disaster Prevention Grant Program After Court Order 
Federal Judge Orders Refund of Trump’s Emergency Tariffs, Potentially Returning Up to $182 Billion 
Stellantis Shareholder Fraud Lawsuit Dismissed by U.S. Judge 
China Opens Door to Stronger U.S. Trade Ties Amid Rising Tensions 
WTO Reform Talks Begin in Cameroon Amid Global Trade Tensions 
Gold Prices Climb as Middle East Ceasefire Talks Stir Market Optimism 
Anthropic Sues Pentagon Over AI Blacklist, Citing Free Speech Violations 
Dollar Strengthens as U.S.-Iran Peace Talks Send Mixed Signals 
Palestinian Activist Leqaa Kordia Released from U.S. Immigration Detention After Judge's Order 
Johnson & Johnson disclosed that it spent $800 million in settling "substantially all" of the roughly 9,000 cases by men who claimed having developed excessive breast tissue in using the company's antipsychotic drug Risperdal.
The company said it reached the agreement with lawyers handling the cases, including a lawsuit in Philadelphia by Maryland resident Nicholas Murray, who was awarded an $8 billion in punitive damage by a jury award in 2019. A judge has since reduced the award to $6.8 million.
The lawsuits, filed in Pennsylvania, California, and Missouri, generally accused J&J of failing to warn of the risk called gynecomastia associated with Risperdal, which they claimed were marketed for off-label, unapproved uses with children.
The company denied the allegations.
In 1993, the US Food and Drug Administration approved Risperdal for treating schizophrenia and bipolar mania in adults. It was only in 2006 that it was approved for treating irritability associated with autism in children.
The company separately agreed in 2013 to pay $2.2 billion to settle US criminal and civil probes into its marketing of Risperdal and two other drugs.
In May, the US Supreme Court rejected J&J's bid to overturn a $70 million jury verdict against it for its failure to warn about risks associated with using Risperdal.
